Pisarek Hanna, Stepień Tomasz, Kubiak Robert, Borkowska Edyta, Pawlikowski Marek
Department of Neuroendocrinology, Medical University, Łódź, Poland.
Thyroid Res. 2009 Jan 27;2(1):1. doi: 10.1186/1756-6614-2-1.
Human endocrine tumors often express the somatostatin receptors SSTR 1-5 with different intensity. It has been widely investigated their distribution in pituitary adenomas, brain tumors, adrenal tumors and neuroendocrine tumors in gastrointestinal tract (NET). Some of studies also concern the expression of SSTRs in thyroid tumors but they are mainly limited to parafollicular C cells - derived medullary thyroid carcinomas (MTC). Results of SSTR 1-5 detection in other thyroid pathologies like follicular adenomas and papillary cancers are still scarce and often controversial, depending of investigation method used. The aim of this study was to report the presence of all the 5 subtypes of SSTR (including 2A and 2B SSTR isoforms) in some surgically treated human thyroid tumors by means of immunohistochemistry and real-time PCR method and to correlate the results obtained with both techniques. SSTR 1 protein was expressed in 88.8% of investigated cases, SSTR 2A and 2B both in 44.4%, SSTR 3 in 55.5%, SSTR 4 in 11.2% and SSTR 5 in 33.3%. SSTR 1 is the dominant form in the thyroid gland tumor and hyperplasia. We found positive confirmation of both methods in 88.8% for SSTR 1, 2A, 3 subtypes, in 22.2% for SSTR 4 and in 100% for SSTR 5. It suggests that somatostatin multiligand analogs or selective SSTR 1 agonists may be used in thyroid tumors treatment.
人类内分泌肿瘤常以不同强度表达生长抑素受体SSTR 1 - 5。其在垂体腺瘤、脑肿瘤、肾上腺肿瘤及胃肠道神经内分泌肿瘤(NET)中的分布已得到广泛研究。一些研究也关注SSTRs在甲状腺肿瘤中的表达,但主要局限于滤泡旁C细胞来源的甲状腺髓样癌(MTC)。在其他甲状腺病变如滤泡性腺瘤和乳头状癌中,SSTR 1 - 5检测结果仍然稀少且常存在争议,这取决于所使用的研究方法。本研究的目的是通过免疫组织化学和实时PCR方法报告在一些手术治疗的人类甲状腺肿瘤中所有5种SSTR亚型(包括2A和2B SSTR亚型)的存在情况,并将两种技术获得的结果进行关联。在所研究的病例中,88.8%表达SSTR 1蛋白,44.4%同时表达SSTR 2A和2B,55.5%表达SSTR 3,11.2%表达SSTR 4,33.3%表达SSTR 5。SSTR 1是甲状腺肿瘤和增生中的主要形式。我们发现,对于SSTR 1、2A、3亚型,两种方法的阳性确认率为88.8%;对于SSTR 4为22.2%;对于SSTR 5为100%。这表明生长抑素多配体类似物或选择性SSTR 1激动剂可用于甲状腺肿瘤的治疗。